一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0600 | 0.0300 | 100 | 0.1600 | | 每股净资产（元） | 1.33 | 1.26 | 5.56 | 1.23 | | 每股公积金(元) | 1.67 | 1.67 | 0 | 1.67 | | 每股未分配利润(元) | -1.43 | -1.49 | 4.03 | -1.53 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 6.89 | 5.29 | 30.25 | 4.63 | | 净利润(亿元) | 0.47 | 0.27 | 74.07 | 1.26 | | 净资产收益率(%) | 4.50 | 2.65 | 69.81 | 14.12 | 数据四舍五入，查看更多财务数据>> 不分配不转增 前十大流通股东累计持有： 21756.62万股，累计占流通股比： 27.08%，较上期变化： -527.70万股。 ...

Financial Performance - The company's operating revenue for 2024 reached ¥688,791,514.90, representing a 30.10% increase compared to ¥529,447,502.52 in 2023[22] - The net profit attributable to shareholders for 2024 was ¥46,854,048.65, a significant increase of 76.26% from ¥26,582,643.81 in the previous year[22] - The net profit after deducting non-recurring gains and losses was ¥39,375,335.61, up 56.33% from ¥25,186,787.21 in 2023[22] - The total assets at the end of 2024 were ¥1,303,178,909.04, reflecting a 6.68% increase from ¥1,221,559,067.16 at the end of 2023[22] - The net assets attributable to shareholders increased by 4.80% to ¥1,065,690,539.17, compared to ¥1,016,847,716.12 at the end of 2023[22] - The basic earnings per share for 2024 were ¥0.06, doubling from ¥0.03 in 2023[22] - The weighted average return on equity for 2024 was 4.50%, an increase of 1.85 percentage points from 2.65% in 2023[22] Cash Flow and Investments - The net cash flow from operating activities decreased by 42.25% to ¥51,056,974.83, down from ¥88,411,728.33 in 2023[22] - Operating cash inflow increased by 27.71% to ¥704,260,892.49 in 2024, primarily due to increased sales collections[62] - Operating cash outflow rose by 41.06% to ¥653,203,917.66, mainly due to increased inventory levels corresponding to higher sales[62] - Investment cash inflow slightly decreased by 1.02% to ¥508,268,850.44, while investment cash outflow decreased by 9.79% to ¥487,696,883.30[60] - Net cash flow from investment activities improved significantly by 175.78% to ¥20,571,967.14, attributed to the redemption of financial products[63] - The company reported a net increase in cash and cash equivalents of ¥61,172,552.88, a 20.30% increase compared to the previous year[60] Revenue Sources and Product Performance - The infrared therapy sauna series contributed CNY 488.37 million, accounting for 70.90% of total revenue, with a year-on-year growth of 27.85%[50] - The company's revenue from the far-infrared therapy series reached ¥488,366,756.97, with a gross margin of 44.09%, showing a year-on-year revenue increase of 27.85%[52] - Sales volume of the far-infrared therapy series increased by 35.91% to 60,761 units, while production volume rose by 42.97% to 61,884 units, driven by increased market orders[54] - The portable sauna series experienced a significant sales volume increase of 172.26% to 97,610 units, attributed to a substantial rise in orders for newly developed products[54] Research and Development - The company has intensified its R&D efforts, leading to improved product quality and market competitiveness, with successful certifications from multiple international standards[37] - The company plans to increase R&D investment to enhance product competitiveness and promote technological innovation[88] - The company’s R&D expenses increased by 29.14% to ¥11,697,173.96, indicating a commitment to enhancing product development[59] - R&D investment amounted to ¥11,697,173.96 in 2024, representing 1.70% of operating revenue, a slight decrease from 1.71% in 2023[60] - The number of R&D personnel increased by 17.24% from 58 in 2023 to 68 in 2024, with a proportion of 14.05% of total employees[60] Market Strategy and Expansion - The company operates in the health industry, which is experiencing growth driven by aging population trends and increasing health awareness, positioning it for future expansion[31] - The company is focusing on optimizing its market layout to ensure stable growth in a dynamic international market environment[37] - The company is actively exploring new growth points and business models to adapt to the complex economic environment[33] - Market expansion plans include entering two new regions, which are projected to increase market share by 10%[113] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million RMB for potential deals[114] Corporate Governance and Compliance - The company emphasizes the importance of maintaining a transparent and timely information disclosure system[90] - The company will enhance internal control management and governance levels to ensure compliance and protect investor rights[90] - The board of directors consists of six members, including two independent directors, ensuring compliance with governance standards[97] - The company has established a transparent performance evaluation and incentive mechanism for its management team[100] - The company strictly adheres to information disclosure regulations, ensuring timely and accurate communication with investors[100] Employee and Management Structure - The total number of employees at the end of the reporting period is 484, including 390 from the parent company and 94 from major subsidiaries[128] - The professional composition includes 318 production personnel, 41 sales personnel, 68 technical personnel, 20 financial personnel, and 37 administrative personnel[128] - The company has a performance bonus system linked to annual business objectives, effectively motivating employee engagement and creativity[129] - Annual training plans are developed based on departmental needs and company strategies, enhancing the skills of management and technical personnel[130] Risk Management - The management has outlined potential risks and countermeasures in the report, emphasizing the importance of investor awareness regarding future plans and forecasts[4] - The company recognizes international market risks due to uncertainties in U.S. tariff policies and plans to diversify market strategies to mitigate these risks[90] - Raw material costs constitute a significant portion of operating costs, and the company will adjust procurement strategies and inventory levels to mitigate the impact of price fluctuations[91] Legal and Regulatory Matters - The company has a pending lawsuit involving a claim of ¥4,000,000 (approximately $570,000) against Anhui Lejin Junze Health Management Co., Ltd. for loan repayment[149] - The court ruled that the defendant must repay the principal amount of ¥4,000,000 and interest, with the interest calculated at an annual rate of 5%[149] - The company has not faced any penalties from securities regulatory authorities for its directors and supervisors in the past three years[118] - There were no significant related party transactions reported during the period, including asset acquisitions or joint investments[153][154] Audit and Financial Reporting - The audit opinion for the financial statements is a standard unqualified opinion, indicating fair representation of the company's financial status as of December 31, 2024[186] - The financial statements were audited by Zhongzheng Tiantong Accounting Firm, with the audit report signed on April 21, 2025[186] - The audit procedures included evaluating the effectiveness of internal controls related to revenue recognition and analyzing revenue growth by product category and customer[192][193]

预告发布后5日股价上涨的占比72.73%。 资金面上，该股今日主力资金净流入264.54万元，近5日资金净流出227.14万元。 （数据宝） 融捷健康（300247）1月22日发布2024年业绩预增公告，预计实现净利润为4200.00万元~4800.00万元， 净利润同比增长58.00%~80.57%。 证券时报•数据宝统计显示，融捷健康今日收于3.46元，下跌1.14%，日换手率为1.48%，成交额为 4121.30万元，近5日下跌2.54%。 通过对2024年业绩预增50%以上的个股走势进行统计发现，预告发布后当日股价上涨的占比69.38%，股 价发布当日股价涨停的有22家。 ...

Financial Projections - The estimated net profit attributable to shareholders for 2024 is projected to be between 42 million and 48 million yuan, representing a year-on-year increase of 58.00% to 80.57% compared to 26.58 million yuan in the previous year[4]. - The estimated net profit after deducting non-recurring gains and losses is projected to be between 34 million and 40 million yuan, indicating a year-on-year growth of 34.99% to 58.81% from 25.19 million yuan in the previous year[4]. Market Expansion - The company is actively expanding into overseas markets, contributing to an increase in operating income compared to the previous year[6]. Financial Reporting - The fair value of investment properties has decreased, leading to a discrepancy between the growth rates of net profit attributable to shareholders and net profit after deducting non-recurring gains and losses[6]. - The financial data presented is preliminary and has not been audited by the accounting firm, but there are no significant discrepancies in financial data discussions with the accounting firm[5].

证券代码：300247 证券简称：融捷健康 公告编号：2024-030 融捷健康科技股份有限公司 2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会没有否决或修改提案的情况； 2、本次股东大会没有新提案提交表决的情况，没有变更前次股东大会决议 的情况； 3、本次股东大会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召集人：公司董事会。 2、会议主持人：公司董事长邢芬玲。 （1）现场会议召开时间：2024 年 11 月 11 日（星期一）下午 14：30。 （2）网络投票时间：2024 年 11 月 11 日。 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 11 月 11 日上午 9:15-9:25，9:30-11:30 和下午 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2024 年 11 月 11 日上午 9：15 至下午 15：00 期间的任意时间。 4、现场会议地点：安徽省合肥市高新区合欢路 ...

安徽睿正律师事务所 法律意见书 2024年第一次临时股东大会的法律意见书 安徽睿正律师事务所 二〇二四年十一月十一日 安徽睿正律师事务所 法律意见书 安徽睿正律师事务所 关于融捷健康科技股份有限公司 安徽睿正律师事务所 2024 年第一次临时股东大会的法律意见书 关于融捷健康科技股份有限公司 睿正证券字[2024]第 058 号 致：融捷健康科技股份有限公司 根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司 股东大会规则》、《律师事务所从事证券业务管理办法》等法律法规、规范性文 件以及公司现行章程的规定，安徽睿正律师事务所接受融捷健康科技股份有限公 司（以下简称"融捷健康公司"或"公司"）的委托，指派盖晓峰、朱敏律师（以 下简称"本所律师"）就公司 2024 年第一次临时股东大会（以下简称"本次股 东大会"）的召集、召开程序、参加出席会议人员的资格、表决程序等有关事宜 出具本法律意见书。 本所律师依据本法律意见书出具日前已经发生或存在的事实和本所律师对 我国现行法律、法规及规范性文件的理解发表法律意见。 本所律师已经对公司提供的与本次股东大会有关的文件、资料进行审查判断， 并据此出具本法律意 ...

证券代码：300247 证券简称：融捷健康 公告编号：2024－029 融捷健康科技股份有限公司 关于股价异动的公告 5、股票交易异常波动期间，未发生公司控股股东、实际控制人及持股 5% 以上的股东、公司董事、监事、高级管理人员买卖本公司股票的行为。 三、其他说明 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 融捷健康科技股份有限公司（以下简称"公司"）股票（证券代码： 300247，证券简称：融捷健康）于 2024 年 10 月 25 日、10 月 28 日、10 月 29 日连续三个交易日收盘价格涨幅偏离值累计达到 30%以上，根据深圳证券交易 所（以下简称"深交所"）的有关规定，属于股票交易异常波动的情况。 二、公司关注并核实相关情况 本公司董事会通过电话及函询方式，对公司控股股东、实际控制人及持股 5%以上股东、公司全体董事、监事及高级管理人员就相关问题进行了核实： 1、公司前期披露的信息不存在需要更正、补充之处； 2、近期公司内外部经营环境未发生重大变化，经营情况正常； 3、公司、控股股东和实际控制人不存在关于公司的应披露而未 ...

融捷健康科技有限公司董事、监事薪酬及津贴实施方案 融捷健康科技股份有限公司 董事、监事薪酬及津贴实施方案 第一章 总 则 第一条 为了保障融捷健康科技股份有限公司（下称"公司"）董事、监事 依法履行职责，健全公司薪酬管理体系，根据《中华人民共和国公司法》、《上 市公司治理准则》及《关于在上市公司建立独立董事制度的指导意见》等有关法 律法规、规范性文件和《融捷健康科技股份有限公司章程》（以下简称"《公司 章程》"）的有关规定，特制定本方案。 第二条 本方案所指董事、监事是指公司董事会组成人员、监事会组成人员， 具体包括：内部董事、外部董事、独立董事、内部监事、外部监事。 内部董事，是指与公司之间签订聘任合同或劳动合同的公司员工或公司管理 人员兼任的董事； 外部董事，是指不在公司担任除董事外的其他职务的非独立董事； 独立董事，是指公司按照《关于在上市公司建立独立董事的指导意见》的规 定聘请的，与公司及其主要股东不存在可能妨碍其进行独立客观判断关系的董事； 内部监事，是指与公司之间签订聘任合同或劳动合同的公司员工或公司管理 人员兼任的监事（包括职工监事）； 外部监事，是指不在公司担任除监事外的其他职务的监事。 第二 ...

证券代码：300247 证券简称：融捷健康 公告编号：2024－024 融捷健康科技股份有限公司 第六届董事会第十二次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 融捷健康科技股份有限公司（以下简称"公司"、"融捷健康"）第六届 董事会第十二次会议通知于 2024 年 10 月 19 日以电子邮件的形式向各位董事发 出。本次会议于 2024 年 10 月 24 日下午以现场结合通讯的方式召开，会议由董 事长邢芬玲女士主持，本次会议应出席会议董事 6 人，实际出席会议董事 6 人。 本次会议的召集、召开及表决程序符合《公司法》等相关法律法规以及《公司 章程》的有关规定；本次会议决议合法、有效。 二、董事会会议审议情况 1、审议通过《关于公司<2024年第三季度报告>的议案》 董事会认为：公司编制《2024 年第三季度报告》的程序符合法律、行政法 规和中国证监会的规定，报告内容公允地反映了公司的经营成果及财务状况， 报告所披露的信息真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏。 本议案已经公司董事会审计委员会会议审议 ...

关于向银行申请综合授信的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 融捷健康科技股份有限公司（以下简称"公司"）于 2024 年 10 月 24 日召开 第六届董事会第十二次会议和第六届监事会第九次会议，审议通过了《关于向 银行申请综合授信的议案》，具体情况如下： 一、本次向银行申请综合授信额度的基本情况 根据公司经营发展的需要，为降低融资成本、提高资金使用效率，公司拟 向银行申请不超过人民币 1 亿元的综合授信额度，本次向银行申请综合授信额 度事项的有效期为第六届董事会第十二次会议决议之日起一年内。 授信形式及用途包括但不限于流动资金贷款、承兑汇票、保函、信用证、 票据贴现等综合业务，具体合作银行及最终融资额、形式后续将与有关银行进 一步协商确定，并以正式签署的协议为准。在上述授信额度内，根据公司资金 状况和业务需要适时向银行申请融资敞口余额不超过人民币 1 亿元的融资，并 在授权期限内可循环滚动使用。 为办理上述银行综合授信额度申请及后续相关借款事项，拟授权公司总经 理或其指定的授权人代表公司在上述授信额度内办理相关手续，并在上述授信 额度内签署一切 ...